1. [CASE 1 — QUESTION 1]
A 76-year-old man with ischemic cardiomyopathy (EF 35%) has been on amiodarone 200 mg daily for 7 years for ventricular arrhythmia suppression. He presents with a 10-week history of progressive exertional dyspnea, dry nonproductive cough, and low-grade fever. His echocardiogram shows no change in EF and no new wall motion abnormalities. Chest X-ray demonstrates new bilateral perihilar interstitial infiltrates. Which of the following represents the most appropriate immediate next step?
A) Start empiric broad-spectrum antibiotics and obtain sputum cultures, community-acquired pneumonia is the most likely diagnosis given the fever, and amiodarone should be continued while the infectious workup is completed
B) Obtain high-resolution CT of the chest and discontinue amiodarone, the clinical presentation is consistent with amiodarone pulmonary toxicity, which requires drug discontinuation and further imaging characterization before other management decisions
C) Increase the furosemide dose and restrict sodium, the bilateral infiltrates most likely represent worsening heart failure from progressive ischemic cardiomyopathy despite a preserved EF on echocardiogram
D) Check TSH and free T4 urgently, amiodarone-induced hyperthyroidism causing high-output cardiac failure is the most likely cause of the bilateral infiltrates and dyspnea in a patient on long-term amiodarone
E) Refer for bronchoscopy with transbronchial biopsy, confirmation of foamy macrophages on pathology is required before amiodarone can be safely discontinued in a patient dependent on it for arrhythmia suppression
ANSWER: B
Rationale:
The clinical triad of progressive dyspnea, nonproductive cough, low-grade fever, and bilateral interstitial infiltrates after 7 years of amiodarone therapy in a patient with a preserved EF on echocardiogram is the classic presentation of amiodarone pulmonary toxicity, specifically interstitial pneumonitis. The appropriate immediate next step is high-resolution CT of the chest to characterize the pattern and extent of infiltrates (typically ground-glass opacification and consolidation in a peripheral or perihilar distribution), combined with immediate discontinuation of amiodarone. Corticosteroids are added in severe or progressive cases.
Option A: Option A incorrectly prioritizes infectious workup and continues amiodarone: while pneumonia must be in the differential, the clinical context makes drug toxicity the primary concern, and continuing amiodarone while awaiting cultures delays necessary discontinuation.
Option C: Option C incorrectly attributes the infiltrates to heart failure: the preserved and unchanged EF makes cardiac pulmonary edema unlikely, and the interstitial pattern with fever points to an inflammatory parenchymal process rather than hydrostatic edema.
Option D: Option D incorrectly prioritizes thyroid evaluation: amiodarone thyrotoxicosis causes high-output failure, but the preserved EF, absence of tachycardia, and parenchymal infiltrates point to pulmonary toxicity rather than thyroid-driven pulmonary edema.
Option E: Option E overstates the requirement for bronchoscopy: foamy macrophages on biopsy are not required before discontinuing amiodarone; the clinical and CT findings are sufficient to act on, and delaying discontinuation to obtain biopsy confirmation would be harmful.
2. [CASE 1 — QUESTION 2]
Continuing the case: HRCT confirms bilateral ground-glass opacification with peripheral consolidation consistent with amiodarone pulmonary toxicity. Amiodarone has been discontinued. The patient asks whether this complication could have been detected earlier. Which of the following correctly describes the monitoring protocol that should have been in place throughout his 7 years of therapy?
A) Annual serum amiodarone levels with dose reduction if levels exceeded 2.5 mcg/mL, toxicity correlates directly with plasma concentration, and monitoring levels is more predictive than symptom-based surveillance
B) Echocardiogram every 6 months to detect amiodarone-induced cardiomyopathy before it manifests as pulmonary congestion and bilateral infiltrates on chest imaging
C) Thyroid function tests alone every 3 months, thyroid dysfunction is the most common toxicity and is a sensitive early marker that predicts imminent pulmonary involvement requiring drug discontinuation
D) Baseline chest X-ray and pulmonary function tests at drug initiation, then annually throughout therapy, with high-resolution CT obtained when new respiratory symptoms develop, this protocol is designed to detect pulmonary toxicity at an early and potentially reversible stage
E) No scheduled surveillance is required for asymptomatic patients on maintenance doses of 200 mg daily, at this dose the annual pulmonary toxicity risk is below 0.5%, making routine monitoring unjustifiable on a cost-effectiveness basis
ANSWER: D
Rationale:
The standard amiodarone monitoring protocol for pulmonary toxicity requires a baseline chest X-ray and pulmonary function tests at initiation, followed by annual chest X-ray and pulmonary function tests throughout the duration of therapy. When new respiratory symptoms develop, high-resolution CT of the chest is indicated to characterize any parenchymal changes. This systematic annual surveillance is intended to detect early, potentially reversible pulmonary toxicity before it progresses to clinically significant pneumonitis. Pulmonary toxicity incidence is approximately 1 to 5% per year, cumulative over years of therapy.
Option A: Option A incorrectly states that serum amiodarone levels predict toxicity: plasma amiodarone concentrations do not reliably correlate with organ toxicity risk because tissue accumulation, not plasma level, drives toxicity; routine level monitoring is not part of the standard surveillance protocol.
Option B: Option B incorrectly substitutes echocardiography for pulmonary surveillance: amiodarone does not cause cardiomyopathy, and echocardiograms are not part of the standard amiodarone toxicity monitoring protocol.
Option C: Option C incorrectly states that thyroid function tests are a surrogate marker for pulmonary toxicity: thyroid and pulmonary toxicities are independent complications of amiodarone; abnormal TFTs do not predict or precede pulmonary involvement.
Option E: Option E incorrectly states that monitoring is unnecessary at 200 mg daily: pulmonary toxicity occurs at maintenance doses and the 1 to 5% annual incidence over a 7-year course represents a cumulative risk that fully justifies systematic annual surveillance.
3. [CASE 1 — QUESTION 3]
Continuing the case: Amiodarone has been discontinued and oral prednisolone started. His cardiologist explains that thyroid function monitoring must continue even though amiodarone has been stopped. Which of the following correctly explains why post-discontinuation thyroid monitoring is mandatory and for how long?
A) Thyroid monitoring must continue for at least 12 months after amiodarone discontinuation because amiodarone's half-life of 40 to 55 days means tissue concentrations decline very slowly, the iodine load and drug effects persist for months, and thyroid dysfunction can develop or progress well after the last dose
B) Thyroid monitoring can stop 4 weeks after amiodarone discontinuation once plasma amiodarone levels have cleared below the detection threshold, as thyroid effects are entirely dependent on circulating drug concentrations rather than tissue accumulation
C) Thyroid monitoring must continue indefinitely after amiodarone discontinuation because the iodine incorporated into thyroid follicular cells during long-term therapy cannot be cleared and creates permanent risk of thyroid dysfunction regardless of drug washout
D) Post-discontinuation thyroid monitoring is required for only 6 weeks because the Wolff-Chaikoff effect that drives hypothyroidism resolves within this timeframe as excess iodide is cleared through normal renal excretion
E) Thyroid monitoring after amiodarone discontinuation is unnecessary if thyroid function was normal at the time of the last dose, as toxicity only develops during active drug exposure and resolves within 2 weeks of stopping
ANSWER: A
Rationale:
Amiodarone's extraordinary pharmacokinetic profile drives the requirement for post-discontinuation monitoring. Its volume of distribution of 60 to 100 L/kg and half-life of 40 to 55 days mean that tissue concentrations, particularly in fat and liver, decline very slowly after the last dose. Clinically significant amiodarone levels may persist for 6 to 12 months after discontinuation, and the sustained iodine load from tissue-stored drug continues to exert thyroid effects during this period. Thyroid dysfunction, including both hypothyroidism and hyperthyroidism, can develop or worsen after amiodarone is stopped, making monitoring for at least 12 months after the last dose a standard requirement.
Option B: Option B incorrectly states that thyroid effects depend only on circulating plasma concentrations: the relevant concentrations are in tissue, and plasma clearance occurs much faster than tissue clearance; thyroid effects persist long after plasma levels become undetectable.
Option C: Option C overstates the duration: monitoring is required for at least 12 months, not indefinitely; once tissue amiodarone has cleared, the iodine-related risk resolves.
Option D: Option D incorrectly limits post-discontinuation monitoring to 6 weeks based on the Wolff-Chaikoff effect: the Wolff-Chaikoff effect is a transient autoregulatory mechanism and does not account for the full spectrum of amiodarone thyroid toxicity; tissue-stored drug continues to release iodine for months.
Option E: Option E incorrectly states that normal thyroid function at discontinuation eliminates subsequent risk: thyroid dysfunction can develop after stopping amiodarone as tissue stores gradually release drug and iodine during washout.
4. [CASE 1 — QUESTION 4]
Continuing the case: Three months after amiodarone discontinuation, the pulmonary toxicity has resolved on CT. The cardiologist now needs to select a new antiarrhythmic agent for ventricular arrhythmia suppression. The patient has HFrEF (EF 35%) and creatinine clearance of 55 mL/min. Which of the following is the most appropriate antiarrhythmic choice?
A) Sotalol 80 mg twice daily with in-hospital initiation, combined Class II and III activity provides effective ventricular arrhythmia suppression in patients with structural heart disease, and his EF of 35% is at the border of acceptable use
B) Flecainide 100 mg twice daily: Class Ic agents are safe in HFrEF once amiodarone has been discontinued, as the CAST contraindication applies specifically to the combination of Class Ic agents with amiodarone metabolites present in tissue
C) Dofetilide 250 mcg twice daily with mandatory in-hospital initiation and QTc monitoring, as one of only two antiarrhythmic agents with demonstrated safety in HFrEF (DIAMOND-CHF), and with dose adjustment for CrCl 40 to 60 mL/min, it is an appropriate choice
D) Dronedarone 400 mg twice daily, it avoids amiodarone's pulmonary toxicity risk through its non-iodinated structure, and at an EF of 35% it falls within the range where ANDROMEDA data suggest acceptable safety
E) Propafenone 150 mg three times daily: Class Ic agents are safe in HFrEF provided the QTc is below 440 ms, and propafenone's mild beta-blocking activity provides additional benefit in ischemic cardiomyopathy
ANSWER: C
Rationale:
In HFrEF with EF 35%, the antiarrhythmic options are severely restricted. Dofetilide is one of only two agents with demonstrated safety in this population: the DIAMOND-CHF trial enrolled patients with EF below 35% and demonstrated neutral mortality with dofetilide versus placebo. His CrCl of 55 mL/min falls in the 40 to 60 mL/min range, requiring dose reduction to 250 mcg twice daily with mandatory in-hospital initiation and QTc monitoring after each dose.
Option A: Option A is incorrect: sotalol should be avoided in patients with EF below 40% due to its beta-blocking negative inotropic effect and the mortality signal from the SWORD trial with d-sotalol in LV dysfunction; an EF of 35% is not at an acceptable border for sotalol.
Option B: Option B is incorrect: flecainide is contraindicated in structural heart disease including HFrEF by the CAST evidence; this contraindication applies regardless of whether amiodarone metabolites remain in tissue and does not resolve with amiodarone discontinuation.
Option D: Option D is incorrect: dronedarone is contraindicated by ANDROMEDA in patients with HFrEF or recently decompensated HF; an EF of 35% is within the contraindicated range, not at an acceptable threshold.
Option E: Option E is incorrect: propafenone is a Class Ic agent and is contraindicated in structural heart disease including HFrEF by the same CAST-derived evidence as flecainide; QTc below 440 ms does not waive this structural contraindication.
5. [CASE 2 — QUESTION 1]
A 64-year-old woman with paroxysmal atrial fibrillation, hypertension, and stage 3a chronic kidney disease (creatinine clearance 52 mL/min) is admitted for sotalol initiation. Her baseline QTc is 428 ms. The admitting resident plans to start sotalol 80 mg twice daily using the standard dosing regimen. Which of the following correctly identifies the error in this plan and the appropriate modification?
A) The error is that sotalol is absolutely contraindicated in any patient with atrial fibrillation, sotalol is indicated only for ventricular arrhythmias, and dronedarone should be used instead for AF rhythm control regardless of renal function
B) The error is that 80 mg twice daily is too low, sotalol should be initiated at 120 mg twice daily in patients with AF to achieve adequate IKr blockade for rhythm control, with the dose titrated down only if QTc exceeds 480 ms
C) The error is that QTc of 428 ms is above the threshold for sotalol initiation, sotalol requires a baseline QTc below 400 ms, and a QTc of 428 ms represents a relative contraindication requiring cardiology consultation before proceeding
D) There is no error: 80 mg twice daily is the correct starting dose for sotalol in AF, CrCl of 52 mL/min is above the contraindication threshold of 40 mL/min, and 3 days of continuous in-hospital telemetry is the appropriate monitoring plan
E) The error is that a CrCl of 52 mL/min requires dosing interval extension to every 36 to 48 hours rather than standard twice-daily dosing, standard twice-daily dosing at this creatinine clearance would cause drug accumulation and amplify QTc prolongation beyond the safe threshold
ANSWER: E
Rationale:
Sotalol is eliminated entirely unchanged by the kidneys. At a CrCl of 52 mL/min, which falls in the 40 to 60 mL/min range, standard twice-daily dosing produces drug accumulation between doses that amplifies QTc prolongation and increases TdP risk. The required adjustment is extension of the dosing interval to every 36 to 48 hours, not dose reduction. Standard twice-daily dosing is appropriate only for CrCl above 60 mL/min. The mandatory 3-day in-hospital monitoring requirement applies regardless of the adjusted interval.
Option A: Option A incorrectly states that sotalol is contraindicated in AF: sotalol is guideline-supported for rhythm control in AF and AFL, particularly in patients without significant structural heart disease or severe renal impairment.
Option B: Option B incorrectly states that 120 mg twice daily is the required initiation dose: sotalol initiation always begins at 80 mg per dose (or equivalent adjusted interval) regardless of indication; higher doses are used only if initial doses are well tolerated and inadequate for arrhythmia control.
Option C: Option C incorrectly states that a baseline QTc of 428 ms exceeds the sotalol initiation threshold: the threshold for sotalol initiation is a baseline QTc below 450 ms; 428 ms is within the acceptable range.
Option D: Option D incorrectly states there is no error: standard twice-daily dosing at CrCl 52 mL/min is the specific error; interval extension is required in the 40 to 60 mL/min range.
6. [CASE 2 — QUESTION 2]
Continuing the case: Sotalol is initiated at the correct dose interval for her creatinine clearance. On day 2, two hours after her morning dose, telemetry shows the QTc has increased from 428 ms at baseline to 516 ms. She is asymptomatic and in sinus rhythm. Serum potassium is 3.8 mEq/L and magnesium is 1.8 mg/dL. What is the correct action?
A) Continue sotalol at the current dose and recheck QTc in 6 hours, a QTc of 516 ms represents the expected degree of QT prolongation at steady state for sotalol at this dose level and does not require intervention in an asymptomatic patient
B) Discontinue sotalol immediately, a QTc exceeding 500 ms at any point during in-hospital initiation is a mandatory stopping criterion; continuing at any dose with a QTc of 516 ms carries an unacceptable torsades de pointes risk
C) Reduce the sotalol dose by 50% and continue monitoring, dose reduction is the preferred initial response to QTc prolongation above 500 ms, and the drug can be continued provided QTc returns below 480 ms within 48 hours
D) Administer IV magnesium sulfate 2 g prophylactically and continue sotalol, prophylactic magnesium prevents torsades de pointes during sotalol initiation and allows continuation at the current dose when QTc rises above 500 ms
E) Increase the QTc monitoring frequency to every 2 hours and continue sotalol, the 500 ms threshold applies only to patients with baseline QTc above 440 ms, and her normal baseline QTc of 428 ms permits a higher threshold during initiation
ANSWER: B
Rationale:
The mandatory in-hospital sotalol initiation protocol requires QTc measurement 2 to 3 hours after each dose. If the QTc exceeds 500 ms at any measurement, sotalol must be discontinued. A QTc of 516 ms exceeds this threshold, and the drug must be stopped regardless of the absence of symptoms. After discontinuation, the case should be reassessed: possible contributing factors such as hypomagnesemia at 1.8 mg/dL should be corrected, and an alternative antiarrhythmic strategy considered.
Option A: Option A is incorrect: a QTc of 516 ms has crossed the mandatory stopping threshold and requires immediate drug discontinuation, not observation.
Option C: Option C is incorrect: the stopping criterion for sotalol is QTc exceeding 500 ms; dose reduction does not satisfy this criterion. Unlike dofetilide, which has a step-down dose protocol when QTc exceeds 500 ms, sotalol's prescribing guidelines specify discontinuation, not dose reduction.
Option D: Option D is incorrect: prophylactic magnesium cannot lower the QTc and does not permit continuation of sotalol above the 500 ms threshold; the stopping criterion applies regardless of magnesium supplementation.
Option E: Option E is incorrect: the 500 ms stopping threshold applies to all patients undergoing sotalol initiation regardless of baseline QTc; a normal baseline QTc does not permit a higher threshold during initiation.
7. [CASE 2 — QUESTION 3]
Continuing the case: Sotalol is discontinued after the QTc of 516 ms. That evening, before the magnesium has been fully corrected (current Mg 1.6 mg/dL, K 3.4 mEq/L), the patient develops three episodes of polymorphic ventricular tachycardia with a twisting QRS axis, each preceded by a short-long-short RR interval sequence. Each episode lasts 8 to 12 seconds and terminates spontaneously. Which of the following correctly identifies the mechanism responsible for this arrhythmia pattern?
A) Catecholamine-sensitive triggered activity driven by delayed afterdepolarizations from sympathetic surges, the short-long-short pattern reflects adrenergic bursts that generate DADs above the threshold for triggered firing in cells with elevated intracellular calcium
B) Fixed anatomical re-entry in a zone of slow conduction created by sotalol's sodium channel blocking action in fibrotically remodeled atrial tissue propagating to the ventricles
C) Re-entrant excitation through the AV node using a concealed accessory pathway, producing retrograde conduction that creates the short-long-short interval pattern on the surface ECG
D) Pause-dependent early afterdepolarization formation: the prolonged pause following each premature ventricular beat maximally prolongs action potential duration at the slow effective rate, generating EADs that trigger the next episode, amplified by hypokalemia and hypomagnesemia reducing repolarizing reserve
E) Automaticity from a triggered focus in the right ventricular outflow tract driven by cyclic AMP-mediated depolarization, producing repetitive monomorphic VT that appears polymorphic due to rate-dependent conduction aberrancy
ANSWER: D
Rationale:
The short-long-short RR interval sequence is the hallmark of pause-dependent torsades de pointes. Each episode is triggered by the following sequence: a premature ventricular beat creates a short RR interval, followed by a compensatory pause (long RR interval), during which APD is maximally prolonged at the slow effective rate due to reverse use-dependence of IKr blockade from residual sotalol. This combination generates early afterdepolarizations (EADs) that trigger the next TdP episode. The electrolyte abnormalities present, hypokalemia at 3.4 mEq/L and hypomagnesemia at 1.6 mg/dL, reduce the outward repolarizing reserve and further amplify APD prolongation, lowering the EAD threshold.
Option A: Option A incorrectly identifies the mechanism as catecholamine-sensitive DAD-driven triggered activity: the short-long-short pattern and pause-dependence are the signatures of EAD-mediated TdP, not DAD-mediated arrhythmia; DAD-driven arrhythmias typically show a different initiating pattern and are associated with digitalis toxicity or catecholamine excess.
Option B: Option B incorrectly attributes the arrhythmia to fixed anatomical re-entry from sodium channel blockade: sotalol does not meaningfully block sodium channels, and fixed re-entrant VT is typically monomorphic, not the twisting polymorphic pattern of TdP.
Option C: Option C incorrectly identifies an accessory pathway as the mechanism: the arrhythmia described is ventricular in origin and polymorphic, inconsistent with AV nodal re-entry through an accessory pathway, which produces regular narrow or wide-complex tachycardia.
Option E: Option E incorrectly identifies RVOT automaticity: RVOT VT produces monomorphic VT with a characteristic LBBB morphology and is not associated with the short-long-short triggering pattern or QT prolongation.
8. [CASE 2 — QUESTION 4]
Continuing the case: The patient has now had five TdP episodes in 90 minutes, all self-terminating. IV magnesium sulfate 2 g has been given and repeat K is 3.4 mEq/L. Sotalol remains discontinued. The episodes continue. Which of the following represents the correct next management step?
A) Initiate IV isoproterenol infusion or temporary transvenous overdrive pacing at 90 to 110 bpm to eliminate the post-extrasystolic pauses that are triggering each TdP episode, thereby shortening APD and suppressing EAD formation
B) Administer IV amiodarone 150 mg over 10 minutes to provide counter-regulatory multi-channel blockade and suppress the EAD-mediated triggered activity responsible for the recurrent TdP episodes
C) Perform synchronized DC cardioversion for each TdP episode, repeated cardioversion is the recommended approach for recurrent self-terminating TdP when pharmacologic therapy has failed to terminate individual episodes
D) Administer IV dofetilide 500 mcg to extend the refractory period beyond the vulnerable window and prevent the EADs from propagating into sustained TdP, providing more complete IKr blockade than residual sotalol alone
E) Administer IV adenosine 6 mg as a rapid bolus, recurrent TdP after sotalol discontinuation has an AV nodal re-entrant component that adenosine can interrupt, and its ultra-short half-life prevents prolonged hemodynamic effects
ANSWER: A
Rationale:
Recurrent pause-dependent TdP that persists despite IV magnesium and electrolyte correction is managed by eliminating the pauses that generate EADs. IV isoproterenol infusion increases heart rate by adrenergic stimulation of the sinus node, shortening cycle length and preventing the post-extrasystolic pauses that trigger EAD formation. If isoproterenol is contraindicated or unavailable, temporary transvenous overdrive pacing at 90 to 110 bpm achieves the same result mechanically. By eliminating the long pause in the short-long-short sequence, APD shortens, EADs are suppressed, and TdP terminates. Ongoing aggressive potassium and magnesium correction should accompany this intervention.
Option B: Option B is incorrect: amiodarone is a potent QT-prolonging agent and would worsen the proarrhythmic substrate driving TdP; IV amiodarone is contraindicated in the setting of active QT-prolongation-driven TdP.
Option C: Option C is incorrect: synchronized DC cardioversion terminates an individual sustained TdP episode that has not self-terminated or is hemodynamically compromising, but it does not address the underlying mechanism; recurrent self-terminating pause-dependent TdP requires the heart rate elevation strategy described in Option A, not repeated cardioversion.
Option D: Option D is incorrect: IV dofetilide does not exist as an approved formulation, and adding another IKr blocker in the setting of active TdP driven by QT prolongation would dramatically amplify the proarrhythmic risk.
Option E: Option E is incorrect: TdP is a ventricular arrhythmia driven by EADs, not an AV nodal re-entrant tachycardia; adenosine is ineffective for ventricular arrhythmias and would not address the mechanism.
9. [CASE 3 — QUESTION 1]
A 71-year-old man with heart failure with reduced ejection fraction (EF 29%), persistent atrial fibrillation, and creatinine clearance 44 mL/min has been stable on dofetilide 250 mcg twice daily for 8 months. He is admitted with worsening angina and started on verapamil 80 mg three times daily by the cardiology fellow for rate control during anginal episodes. The attending pharmacist alerts the team to a critical drug interaction. Which of the following correctly identifies the interaction and explains why it is contraindicated?
A) Verapamil blocks IKr directly in ventricular myocardium and adds to dofetilide's IKr blockade, producing additive QT prolongation through a pharmacodynamic mechanism; the combination requires QTc monitoring every 6 hours but does not require discontinuation of either drug
B) Verapamil induces CYP3A4 in the liver, accelerating dofetilide hepatic metabolism and reducing plasma dofetilide levels to subtherapeutic concentrations, increasing the risk of atrial fibrillation recurrence rather than torsades de pointes
C) Verapamil inhibits renal organic cation transporter 2 (OCT2), reducing dofetilide tubular secretion and substantially raising plasma dofetilide levels, amplifying QTc prolongation and creating an unacceptable torsades de pointes risk; verapamil is explicitly contraindicated with dofetilide in prescribing guidelines
D) Verapamil reduces renal blood flow through its negative inotropic effect, secondarily reducing dofetilide glomerular filtration and raising plasma levels in a dose-dependent manner that is manageable by reducing the dofetilide dose by 50%
E) Verapamil competes with dofetilide for binding at myocardial IKr channels, displacing dofetilide from its receptor and reducing the effective drug concentration at the target site, causing therapeutic failure without affecting plasma dofetilide levels
ANSWER: C
Rationale:
Verapamil is an explicit OCT2 inhibitor listed as a contraindicated combination in dofetilide prescribing guidelines. Dofetilide is 80% renally eliminated via OCT2-mediated tubular secretion. When OCT2 is inhibited by verapamil, dofetilide tubular secretion is reduced, drug accumulates, plasma levels rise substantially, and QTc prolongation is amplified to a degree that creates an unacceptable TdP risk. Additionally, verapamil is contraindicated in HFrEF due to its negative inotropic effect, compounding the clinical concern. Verapamil must be discontinued immediately and an alternative rate control strategy employed. Option E is pharmacologically incorrect: verapamil does not compete with dofetilide at IKr channels; these drugs do not share a channel binding site, and dofetilide's plasma levels are raised, not lowered, by the interaction.
Option A: Option A incorrectly identifies the mechanism as pharmacodynamic IKr blockade by verapamil: the primary interaction is pharmacokinetic via OCT2 inhibition, not additive IKr blockade; managing the combination with QTc monitoring does not eliminate the pharmacokinetic drug accumulation.
Option B: Option B inverts the mechanism: verapamil inhibits CYP3A4, it does not induce it; however, dofetilide's primary elimination is renal via OCT2, not hepatic CYP3A4; the clinically important interaction is OCT2 inhibition raising dofetilide levels, not CYP inhibition lowering them.
Option D: Option D incorrectly attributes the interaction to reduced glomerular filtration from negative inotropy: the mechanism is direct OCT2 inhibition at the renal tubule, not an indirect effect on GFR; dose reduction does not satisfy the prescribing contraindication.
10. [CASE 3 — QUESTION 2]
Continuing the case: Verapamil is discontinued. The team asks why the patient was on 250 mcg twice daily rather than the standard 500 mcg twice daily dose. Which of the following correctly explains the dose selection?
A) The 250 mcg twice daily dose was selected because patients with HFrEF require lower dofetilide doses due to reduced hepatic metabolism from congestion-related hepatic dysfunction, which raises dofetilide plasma levels at standard doses
B) The 250 mcg twice daily dose was selected to reduce the absolute TdP risk in a patient with HFrEF, where any QTc prolongation is more dangerous than in patients with structurally normal hearts; this is a risk-adjusted dose reduction rather than a pharmacokinetic adjustment
C) The 250 mcg twice daily dose was selected because the baseline QTc was between 420 and 440 ms at initiation, and dofetilide labeling specifies dose reduction when baseline QTc falls in this intermediate range to minimize the risk of exceeding 500 ms during monitoring
D) The 250 mcg twice daily dose was selected because dofetilide requires dose reduction in all patients above age 65, as elderly patients have reduced OCT2 transporter activity that reduces renal dofetilide secretion even when measured creatinine clearance appears adequate
E) The 250 mcg twice daily dose was selected because dofetilide has four mandatory renal dose tiers based on creatinine clearance: his CrCl of 44 mL/min falls in the 40 to 60 mL/min range, requiring dose reduction from 500 to 250 mcg twice daily to prevent drug accumulation from reduced renal elimination and avoid amplified QTc prolongation and TdP risk
ANSWER: E
Rationale:
Dofetilide's mandatory four-tier renal dose adjustment is based solely on measured creatinine clearance. For CrCl greater than 60 mL/min: 500 mcg twice daily. For CrCl 40 to 60 mL/min: 250 mcg twice daily. For CrCl 20 to 40 mL/min: 125 mcg twice daily. For CrCl below 20 mL/min: contraindicated. This patient's CrCl of 44 mL/min falls in the 40 to 60 mL/min range, requiring 250 mcg twice daily.
Option A: Option A incorrectly attributes the dose reduction to hepatic dysfunction from HFrEF: dofetilide is primarily renally eliminated; hepatic congestion does not meaningfully affect dofetilide metabolism, and hepatic dysfunction is not a basis for dose adjustment.
Option B: Option B incorrectly characterizes the dose reduction as a risk-adjusted decision rather than a pharmacokinetic protocol: the dose tier is determined by CrCl alone, not by cardiac diagnosis or perceived TdP risk.
Option C: Option C incorrectly states that baseline QTc in the 420 to 440 ms range triggers dose reduction: the QTc threshold for dose reduction during initiation is QTc exceeding 500 ms after a dose; baseline QTc below 440 ms is required to initiate but does not by itself determine the dose tier.
Option D: Option D incorrectly attributes the dose reduction to age-related OCT2 reduction as a blanket policy: dofetilide dosing is based on measured CrCl, not age; if CrCl is above 60 mL/min in an elderly patient, the standard 500 mcg dose applies.
11. [CASE 3 — QUESTION 3]
Continuing the case: Verapamil has been stopped and an alternative rate control strategy is being arranged. Two hours after verapamil was given, the QTc is now 508 ms. The patient remains on dofetilide 250 mcg twice daily. What is the correct management of the QTc finding?
A) Continue dofetilide at 250 mcg twice daily and recheck QTc in 24 hours, the elevated QTc is entirely attributable to the verapamil that has now been discontinued, and it will normalize as verapamil clears without any change to the dofetilide regimen
B) Reduce the dofetilide dose to the next lower tier (125 mcg twice daily) and recheck QTc 2 to 3 hours after the next dose, if QTc remains above 500 ms at 125 mcg twice daily, dofetilide must be discontinued; if it falls below 500 ms, the lower dose can be maintained
C) Discontinue dofetilide permanently, a QTc of 508 ms on dofetilide after an OCT2 inhibitor is introduced is a safety threshold violation that mandates permanent discontinuation with no option for dose reduction or rechallenge
D) Administer IV magnesium sulfate 2 g to acutely lower the QTc before the next scheduled dose, magnesium directly reverses QT prolongation caused by IKr blockade and will allow dofetilide continuation at the current dose without further action
E) Continue dofetilide at 250 mcg twice daily and restart verapamil at a 50% reduced dose, at a lower verapamil dose, OCT2 inhibition is insufficient to raise dofetilide levels meaningfully, and the rate control benefit of verapamil outweighs the interaction risk
ANSWER: B
Rationale:
The dofetilide monitoring protocol specifies that if QTc exceeds 500 ms, the dose should be reduced to the next lower tier and QTc rechecked 2 to 3 hours after the subsequent dose at the lower dose level. In this patient, 250 mcg twice daily would be reduced to 125 mcg twice daily. If QTc remains above 500 ms at 125 mcg twice daily, dofetilide must be discontinued. If QTc falls below 500 ms at 125 mcg, the lower dose can be continued. This step-down approach is the standard protocol response to QTc exceeding 500 ms during dofetilide therapy and differs from sotalol, where exceeding 500 ms mandates outright discontinuation. Option E is absolutely incorrect: restarting verapamil at any dose with dofetilide is contraindicated regardless of the dose used; the OCT2 inhibition interaction occurs at standard clinical verapamil doses and cannot be managed by dose reduction.
Option A: Option A is incorrect: although verapamil discontinuation will reduce the OCT2 inhibition over time and lower dofetilide levels, the immediate QTc of 508 ms has crossed the action threshold and requires dose adjustment now, not 24-hour observation.
Option C: Option C is incorrect: permanent discontinuation is required only if QTc remains above 500 ms at the lowest dose tier (125 mcg twice daily); the step-down protocol should be attempted first before concluding that dofetilide cannot be used.
Option D: Option D is incorrect: magnesium does not reverse QT prolongation caused by IKr blockade in a pharmacologically predictable way; it suppresses EADs but does not normalize the QTc, and it cannot be used as a substitute for dose adjustment when the threshold has been crossed.
12. [CASE 3 — QUESTION 4]
Continuing the case: The dose is reduced to 125 mcg twice daily and QTc normalizes to 436 ms. A medical student asks why dofetilide is considered safe in HFrEF when most antiarrhythmic agents are avoided. Which of the following best answers this question?
A) Dofetilide is considered safe in HFrEF because its pure IKr blocking mechanism does not affect myocardial contractility, all antiarrhythmic agents that are avoided in HFrEF carry proarrhythmic risk from sodium channel blockade or negative inotropy, which dofetilide specifically lacks
B) Dofetilide is considered safe in HFrEF because it was the active comparator in the CAST trial, which demonstrated its superiority over flecainide and encainide in patients with structural heart disease including reduced ejection fraction
C) Dofetilide is considered safe in HFrEF because the SWORD trial established that pure IKr blockers without beta-blocking activity are safer than combined Class II/III agents in patients with left ventricular dysfunction
D) Dofetilide is considered safe in HFrEF based on the DIAMOND-CHF trial, which enrolled patients with symptomatic HF and EF below 35% and demonstrated that dofetilide did not increase all-cause mortality compared to placebo, making it one of only two antiarrhythmic agents with this safety demonstration in HFrEF
E) Dofetilide is considered safe in HFrEF because it has no effect on the AV node and does not reduce heart rate, the mortality risk of antiarrhythmic agents in HFrEF is driven by bradycardia-induced hemodynamic compromise, which dofetilide avoids through its selective atrial action
ANSWER: D
Rationale:
The DIAMOND-CHF (Danish Investigations of Arrhythmia and Mortality on Dofetilide in CHF) trial enrolled patients with symptomatic congestive heart failure and ejection fraction below 35% and demonstrated that dofetilide did not increase all-cause mortality compared to placebo. This neutral mortality finding in a population where several other antiarrhythmic agents have demonstrated excess mortality or significant safety concerns is the evidence basis for considering dofetilide safe in HFrEF. Together with amiodarone, it is one of only two antiarrhythmic agents with this demonstration. Option A is partially correct in stating that dofetilide lacks negative inotropy and sodium channel blockade, but this mechanistic reasoning alone does not establish safety; it is the DIAMOND-CHF trial evidence that provides the clinical basis for the safety designation, not mechanistic inference alone.
Option B: Option B incorrectly states that dofetilide was the active comparator in the CAST trial: CAST studied encainide and flecainide in post-MI patients with ventricular ectopy; dofetilide was not involved in CAST.
Option C: Option C incorrectly attributes dofetilide's HFrEF safety to the SWORD trial: SWORD studied d-sotalol, which demonstrated increased mortality in LV dysfunction; it did not study dofetilide and does not support its safety.
Option E: Option E incorrectly states that the mortality risk of antiarrhythmic agents in HFrEF is driven by bradycardia-induced hemodynamic compromise: the mortality risks in HFrEF relate to proarrhythmia, negative inotropy, and other drug-specific mechanisms, not exclusively to bradycardia; this mechanistic reasoning does not establish clinical safety.
13. [CASE 4 — QUESTION 1]
A 68-year-old woman with ischemic cardiomyopathy (EF 31%), NYHA Class II heart failure, and permanent atrial fibrillation presents for a medication review. Her current medications include carvedilol, sacubitril-valsartan, eplerenone, and apixaban. A consultant has suggested adding dronedarone for rhythm control. Which of the following correctly evaluates this proposal?
A) Dronedarone is contraindicated in this patient by two independent trial-based constraints: ANDROMEDA demonstrated excess mortality with dronedarone in HFrEF, and PALLAS demonstrated excess mortality, stroke, and arrhythmia in permanent AF; she meets both contraindication criteria simultaneously
B) Dronedarone is acceptable because her EF of 31% is above the ANDROMEDA threshold of 25%, and the PALLAS finding applies only when dronedarone is used without concurrent beta-blocker therapy; her carvedilol covers the PALLAS risk
C) Dronedarone is acceptable because she has NYHA Class II rather than Class III or IV symptoms; the ANDROMEDA contraindication applies only to Class III or IV heart failure, and Class II is within the approved indication for dronedarone in structural heart disease
D) Dronedarone is contraindicated only by PALLAS because her AF is permanent; the ANDROMEDA contraindication applies to a different population and does not apply to this patient since her last hospitalization for HF was more than 2 years ago
E) Dronedarone is contraindicated only by ANDROMEDA because her EF is below 35%; the PALLAS finding does not apply because she is on beta-blocker therapy, which was the confounding factor that caused the excess events in the permanent AF arm of PALLAS
ANSWER: A
Rationale:
This patient meets both major dronedarone contraindications independently. ANDROMEDA (2008) enrolled patients with severe HFrEF or recently decompensated HF and demonstrated excess mortality, leading to a contraindication in patients with HFrEF and NYHA Class III-IV symptoms or recent decompensation. Her EF of 31% and HFrEF diagnosis place her within the contraindicated population. PALLAS (2011) enrolled patients with permanent AF at cardiovascular risk and was stopped early due to excess stroke, cardiovascular death, and arrhythmia events in the dronedarone arm; her permanent AF independently contraindicated dronedarone before HFrEF was even considered. Both contraindications apply simultaneously and independently.
Option B: Option B incorrectly states the ANDROMEDA EF threshold as 25% and that concurrent beta-blocker therapy mitigates the PALLAS risk: the ANDROMEDA threshold is approximately 35%, placing an EF of 31% firmly within the contraindicated range; beta-blocker use was not identified as the cause of PALLAS events, and the permanent AF contraindication is categorical.
Option C: Option C incorrectly states the ANDROMEDA contraindication applies only to NYHA Class III or IV: guidelines apply the contraindication to any patient with HFrEF and significant LV dysfunction, particularly with any history of recent decompensation; NYHA Class II does not provide a safe harbor.
Option D: Option D incorrectly states that ANDROMEDA does not apply because the last HF hospitalization was more than 2 years ago: the time since last hospitalization does not define the safety boundary for dronedarone in HFrEF; EF and LV dysfunction status are the primary determinants.
Option E: Option E incorrectly attributes the PALLAS excess events to beta-blocker use as a confounding factor: there is no evidence that beta-blocker therapy caused the PALLAS events, and the permanent AF contraindication stands independently of concurrent medications.
14. [CASE 4 — QUESTION 2]
Continuing the case: The consultant asks for an explanation of the mechanism proposed to underlie the ANDROMEDA mortality excess. Which of the following best describes the proposed pharmacological basis?
A) Dronedarone caused excess mortality in ANDROMEDA through direct hepatotoxicity from its benzofuran core structure, which accumulates in hepatocytes of patients with low hepatic blood flow from reduced cardiac output, producing fatal acute liver failure
B) Dronedarone caused excess mortality in ANDROMEDA through IKr-mediated torsades de pointes, occurring at a higher rate in HFrEF patients because reduced cardiac output creates a substrate of chronic bradycardia that amplifies reverse use-dependence
C) Dronedarone's negative inotropic effect from calcium channel blockade combined with its inhibition of the sodium-calcium exchanger (NCX) is proposed to impair the compensatory mechanisms that sustain cardiac output in severely failing hearts, worsening hemodynamics in a population with minimal reserve
D) Dronedarone caused excess mortality in ANDROMEDA through CYP3A4-mediated drug interactions with the background HFrEF medications (beta-blockers, ACE inhibitors, aldosterone antagonists), raising plasma concentrations of these agents to toxic levels
E) Dronedarone's excess mortality in ANDROMEDA was caused by its thyroid toxicity, previously attributed only to amiodarone, which is now recognized to occur with dronedarone despite its non-iodinated structure due to the shared benzofuran scaffold
ANSWER: C
Rationale:
The proposed mechanism for excess mortality in ANDROMEDA involves dronedarone's hemodynamic effects in the severely failing heart. Dronedarone shares amiodarone's multi-channel pharmacology including Class IV L-type calcium channel blockade, which exerts a negative inotropic effect. Additionally, dronedarone inhibits the sodium-calcium exchanger (NCX), an important compensatory mechanism in the failing heart that helps manage calcium homeostasis and maintain contractility. In patients with severe HFrEF and minimal hemodynamic reserve, the combination of reduced inotropy and NCX inhibition is proposed to further impair an already compromised cardiac output, contributing to excess mortality. This mechanistic explanation is supported by the pharmacological profile of the drug.
Option A: Option A incorrectly attributes the ANDROMEDA mortality to hepatotoxicity: post-marketing surveillance has identified hepatotoxicity as a dronedarone concern, but it was not the mechanism of excess mortality in ANDROMEDA; acute liver failure did not account for the trial's early stopping.
Option B: Option B incorrectly attributes the mortality to TdP from reverse use-dependence: dronedarone's TdP risk is described as low to moderate, and TdP was not identified as the primary cause of ANDROMEDA events; the hemodynamic mechanism is the proposed explanation.
Option D: Option D incorrectly attributes the mortality to CYP3A4-mediated interactions raising background medication levels: while dronedarone does inhibit CYP3A4 and can raise levels of certain drugs, this mechanism was not proposed as the cause of ANDROMEDA excess mortality and does not explain the hemodynamic pattern of events observed.
Option E: Option E incorrectly attributes thyroid toxicity to dronedarone: dronedarone was specifically designed to be non-iodinated to avoid amiodarone's thyroid toxicity; iodine-related thyroid effects have not been established as a mechanism for dronedarone mortality in ANDROMEDA.
15. [CASE 4 — QUESTION 3]
Continuing the case: The team asks about the PALLAS trial findings in more detail. Which of the following correctly describes the PALLAS trial design, its primary findings, and the clinical implication?
A) PALLAS enrolled patients with paroxysmal AF and heart failure with preserved ejection fraction and demonstrated that dronedarone reduced cardiovascular hospitalization in this population; the trial was terminated early due to achieving its primary endpoint ahead of schedule
B) PALLAS enrolled patients with newly diagnosed AF within 12 months and demonstrated that early rhythm control with dronedarone was superior to rate control in preventing adverse cardiovascular outcomes, establishing dronedarone as a preferred early rhythm control agent
C) PALLAS enrolled patients with persistent AF refractory to cardioversion and demonstrated that dronedarone was non-inferior to amiodarone for maintaining sinus rhythm; the finding supported dronedarone as an alternative to amiodarone in patients intolerant of its toxicity profile
D) PALLAS enrolled patients with permanent AF and normal ejection fraction and demonstrated that dronedarone reduced stroke risk through an anticoagulant mechanism independent of its antiarrhythmic effect; the trial was stopped early due to unexpected benefit exceeding the pre-specified stopping rule
E) PALLAS enrolled patients with permanent AF at cardiovascular risk and was stopped early due to excess rates of stroke, cardiovascular death, and serious arrhythmia events in the dronedarone arm compared to placebo; the finding established permanent AF as an absolute contraindication to dronedarone regardless of ejection fraction
ANSWER: E
Rationale:
The PALLAS (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy) trial enrolled patients with permanent atrial fibrillation and at least one additional cardiovascular risk factor. It was stopped early due to a significant increase in the rates of stroke, cardiovascular death, and arrhythmia-related events in the dronedarone arm compared to placebo. These findings established permanent AF as an absolute contraindication to dronedarone, applicable regardless of ejection fraction or other cardiac status.
Option A: Option A incorrectly describes the PALLAS population as paroxysmal AF with HFpEF and inverts the outcome: PALLAS enrolled permanent AF patients and was stopped for harm, not benefit.
Option B: Option B incorrectly describes PALLAS as an early rhythm control trial: this describes the EAST-AFNET 4 trial, which studied early rhythm control in newly diagnosed AF; PALLAS studied permanent AF in which rhythm control was no longer being pursued.
Option C: Option C incorrectly describes PALLAS as a non-inferiority comparison of dronedarone versus amiodarone for sinus rhythm maintenance: PALLAS compared dronedarone to placebo in permanent AF patients, not to amiodarone in a rhythm control context.
Option D: Option D incorrectly states that PALLAS demonstrated a stroke-reducing anticoagulant effect and was stopped for unexpected benefit: PALLAS was stopped for harm, specifically excess stroke among other adverse events; the dronedarone arm had more, not fewer, strokes.
16. [CASE 4 — QUESTION 4]
Continuing the case: Dronedarone is clearly contraindicated. The cardiologist now needs to select an appropriate antiarrhythmic strategy for this patient (EF 31%, permanent AF, CrCl 62 mL/min, QTc 434 ms). Which of the following correctly identifies the appropriate options?
A) Rate control with beta-blocker and digoxin is the only appropriate strategy, rhythm control is not indicated in permanent AF, and all antiarrhythmic agents are contraindicated in combined HFrEF and permanent AF
B) Amiodarone for rate and rhythm modulation, or dofetilide 500 mcg twice daily (standard dose for CrCl 62 mL/min) with mandatory in-hospital initiation, these are the only two antiarrhythmic agents with established safety in HFrEF; flecainide, propafenone, sotalol, and dronedarone are all contraindicated
C) Sotalol 80 mg twice daily with in-hospital initiation, her CrCl of 62 mL/min is marginally above the 60 mL/min standard dosing threshold and her EF of 31%, while low, is acceptable for sotalol given that the SWORD contraindication applied specifically to d-sotalol and not the racemic mixture used clinically
D) Flecainide 100 mg twice daily: Class Ic agents are safe in HFrEF if used with concurrent beta-blocker therapy, and the CAST finding applied specifically to patients with frequent ventricular ectopy after MI, not to patients with permanent AF and ischemic cardiomyopathy
E) Amiodarone is the only appropriate antiarrhythmic agent, dofetilide is contraindicated in permanent AF because its IKr-blocking mechanism accelerates AV conduction during AF and increases the ventricular rate rather than suppressing the arrhythmia
ANSWER: B
Rationale:
In a patient with HFrEF (EF 31%) and permanent AF, the antiarrhythmic choices are severely restricted. Amiodarone is the most broadly effective agent and is safe in HFrEF; it also provides rate control through its beta-blocking and calcium channel blocking actions, making it useful in this context. Dofetilide at 500 mcg twice daily (CrCl 62 mL/min is above the 60 mL/min threshold for standard dosing) with mandatory in-hospital initiation is the other appropriate option, supported by DIAMOND-CHF. Flecainide and propafenone are contraindicated by CAST in structural heart disease. Sotalol is avoided with EF below 40% due to negative inotropic beta-blockade and the SWORD signal. Dronedarone is doubly contraindicated.
Option A: Option A incorrectly states that all antiarrhythmic agents are contraindicated: amiodarone and dofetilide are both appropriate rhythm-modifying agents in this population, and rate control alone is not the only strategy available.
Option C: Option C incorrectly states that racemic sotalol is exempt from the SWORD-derived caution: the clinical caution around sotalol in LV dysfunction is based on both the SWORD trial and the pharmacological rationale of negative inotropic beta-blockade at antiarrhythmic doses; the racemic mixture is not exempt.
Option D: Option D is incorrect: flecainide is contraindicated in all structural heart disease with LV dysfunction; the CAST contraindication is not limited to patients with frequent ventricular ectopy after MI and applies broadly to structural heart disease.
Option E: Option E incorrectly states that dofetilide is contraindicated in permanent AF: dofetilide does not accelerate AV conduction; its IKr blockade prolongs refractoriness throughout the heart and is used for both cardioversion and rhythm maintenance in AF regardless of whether the AF is permanent or non-permanent.
17. [CASE 5 — QUESTION 1]
A 70-year-old man with atrial fibrillation, hypercholesterolemia, and hypertension is stable on warfarin (INR 2.4), simvastatin 40 mg nightly, and ramipril. His cardiologist starts amiodarone 200 mg daily for rhythm control. At the 6-week follow-up visit, which drug interaction requires the most urgent attention?
A) Amiodarone reduces ramipril conversion to its active metabolite ramiprilat by inhibiting hepatic esterase activity, reducing blood pressure control and increasing the risk of hypertensive urgency in the context of AF cardioversion
B) Amiodarone inhibits the sodium-hydrogen exchanger in renal tubular cells, impairing potassium excretion and raising serum potassium levels that require weekly monitoring to avoid hyperkalemia when combined with an ACE inhibitor
C) Amiodarone inhibits CYP2C9, reducing metabolism of S-warfarin and displacing warfarin from albumin binding, raising the INR substantially, the warfarin dose should have been reduced by one-third to one-half at amiodarone initiation and INR must be checked urgently given the 6-week delay
D) Amiodarone inhibits the renal organic cation transporter, raising ramipril plasma levels and increasing the risk of angioedema, which is the most serious adverse effect of ACE inhibitor therapy in the setting of amiodarone co-administration
E) Amiodarone has no clinically significant interactions with warfarin, simvastatin, or ramipril at the 200 mg daily maintenance dose, at this dose, CYP enzyme inhibition is insufficient to produce meaningful changes in the plasma levels of any of these three drugs
ANSWER: C
Rationale:
The most urgent interaction at 6 weeks is the amiodarone-warfarin interaction. Amiodarone inhibits CYP2C9 (the primary enzyme metabolizing S-warfarin) and displaces warfarin from albumin binding sites, raising the INR substantially. The interaction builds gradually as amiodarone accumulates in tissues over its 40 to 55 day half-life; at 6 weeks the inhibitory effect is near maximal. The warfarin dose should have been proactively reduced by one-third to one-half at amiodarone initiation, and the INR should have been checked at 1 to 2 weeks and regularly thereafter. At 6 weeks without dose adjustment, there is significant risk of supratherapeutic INR and bleeding. The simvastatin interaction (CYP3A4 inhibition raising statin levels) also requires attention but is less urgently life-threatening than an unmonitored warfarin elevation.
Option A: Option A is incorrect: amiodarone does not inhibit hepatic esterase activity responsible for ramipril conversion; ramipril is converted to ramiprilat by tissue and plasma esterases that are not affected by amiodarone.
Option B: Option B is incorrect: amiodarone does not inhibit the sodium-hydrogen exchanger in a manner that impairs renal potassium excretion; hyperkalemia is a concern with ACE inhibitors plus potassium-sparing agents, not with amiodarone.
Option D: Option D is incorrect: amiodarone does not raise ramipril plasma levels via renal organic cation transport inhibition; ramipril is not significantly eliminated by OCT; angioedema risk from ACE inhibitors is not amplified by amiodarone.
Option E: Option E is incorrect: amiodarone's CYP2C9 inhibition at 200 mg daily is clinically significant and produces meaningful INR elevation; the interaction is not dose-dependent in a way that makes 200 mg daily safe from interaction.
18. [CASE 5 — QUESTION 2]
Continuing the case: The INR is urgently checked and found to be 5.8. The warfarin dose is reduced appropriately. At the same visit, the patient's creatinine kinase (CK) is 1,840 U/L (normal less than 200 U/L) and he reports 3 weeks of muscle aching in his thighs. Which of the following correctly identifies the cause and appropriate management?
A) Amiodarone inhibits CYP3A4, raising simvastatin plasma levels and increasing the risk of statin myopathy, simvastatin should be stopped immediately and switched to pravastatin or rosuvastatin, which are not significantly metabolized by CYP3A4, once the CK normalizes
B) Amiodarone directly damages skeletal muscle mitochondria through its iodine content, producing a myopathy independent of any drug interaction, simvastatin should be continued and amiodarone discontinued as the primary cause of muscle damage
C) The elevated CK results from amiodarone-induced hypothyroidism causing myopathy: TSH should be checked urgently, and if hypothyroidism is confirmed, levothyroxine should be started while continuing both amiodarone and simvastatin
D) Ramipril inhibits ACE in skeletal muscle, reducing local angiotensin II levels and impairing mitochondrial function in a way that is amplified by concurrent statin use, ramipril should be switched to an ARB to resolve the myopathy
E) The elevated CK represents normal variation in a patient taking both amiodarone and simvastatin: CK elevation up to 10 times the upper limit of normal is acceptable in patients on both drugs, and no medication changes are needed provided the patient has no renal impairment
ANSWER: A
Rationale:
Amiodarone is a potent inhibitor of CYP3A4, the primary enzyme responsible for simvastatin and lovastatin metabolism. By inhibiting CYP3A4, amiodarone raises simvastatin plasma levels substantially, increasing the risk of statin-induced myopathy and rhabdomyolysis. FDA labeling for simvastatin specifies that doses above 20 mg should be avoided in patients taking amiodarone. This patient was on simvastatin 40 mg, which is above the safe threshold, and has now developed symptomatic myopathy with CK elevation to 1,840 U/L (approximately 9 times the upper limit of normal). The correct management is to stop simvastatin immediately, hold until CK normalizes, then switch to pravastatin or rosuvastatin, both are eliminated primarily through non-CYP3A4 pathways and do not have clinically significant interactions with amiodarone.
Option B: Option B is incorrect: amiodarone does not directly damage skeletal muscle through iodine toxicity; the peripheral neuropathy associated with amiodarone affects the peripheral nervous system, not skeletal muscle mitochondria directly; continuing simvastatin while discontinuing amiodarone inverts the correct management.
Option C: Option C is incorrect: while amiodarone-induced hypothyroidism can cause myopathy and CK elevation, the context of simvastatin co-administration makes the drug interaction the more likely and immediately actionable cause; TSH should be checked but simvastatin should not continue while CK is this elevated.
Option D: Option D is incorrect: ramipril does not inhibit ACE in skeletal muscle in a manner that amplifies statin myopathy; the ACE inhibitor-statin interaction causing myopathy is not an established clinical mechanism.
Option E: Option E is incorrect: a CK of 1,840 U/L with symptomatic myalgia in the context of a known drug interaction requires medication adjustment; "acceptable CK elevation" thresholds do not apply when there is an identified precipitating drug interaction causing progressive muscle injury.
19. [CASE 5 — QUESTION 3]
Continuing the case: Simvastatin is stopped and the patient asks which statin he can take safely with amiodarone. Which of the following correctly identifies the appropriate statin and explains the pharmacokinetic basis for its safety with amiodarone?
A) Atorvastatin 40 mg daily is the safest choice with amiodarone because atorvastatin is metabolized by CYP2C9, which amiodarone does not inhibit to a clinically meaningful degree at maintenance doses, making the combination safe at all standard atorvastatin doses
B) Rosuvastatin is an appropriate choice because it undergoes minimal CYP3A4 metabolism, with the majority of its elimination occurring through non-CYP hepatic pathways and direct renal excretion, avoiding the drug accumulation produced by CYP3A4 inhibition from amiodarone
C) Fluvastatin is contraindicated with amiodarone because it is the only statin metabolized entirely by CYP2C9, which amiodarone inhibits potently; fluvastatin plasma levels would rise 4 to 5 fold in the presence of amiodarone, causing rhabdomyolysis in all patients
D) No statin can be safely co-administered with amiodarone because amiodarone inhibits both CYP2C9 and CYP3A4, which together account for the metabolism of all currently available statins; amiodarone therapy therefore requires discontinuation of statin therapy for the duration of treatment
E) Pravastatin is an appropriate choice because it is primarily eliminated through non-CYP pathways including sulfation and direct biliary excretion, without significant CYP3A4 or CYP2C9 involvement, avoiding the interaction that caused myopathy with simvastatin
ANSWER: E
Rationale:
Pravastatin is an appropriate statin for patients on amiodarone because its elimination does not rely significantly on CYP3A4 or CYP2C9, the enzymes inhibited by amiodarone. Pravastatin undergoes sulfation and direct biliary secretion as its primary elimination pathways, making it pharmacokinetically independent of amiodarone's CYP inhibitory effects. Plasma pravastatin levels are therefore not significantly raised by amiodarone. Option B also identifies rosuvastatin as appropriate and is pharmacokinetically accurate (rosuvastatin undergoes minimal CYP3A4 metabolism), but Option E is the more complete and precisely stated correct answer for the mechanism specified in the question.
Option A: Option A incorrectly identifies atorvastatin as safe: atorvastatin is metabolized primarily by CYP3A4, the enzyme amiodarone potently inhibits; atorvastatin plasma levels rise significantly with CYP3A4 inhibition and atorvastatin is not the preferred statin with amiodarone at standard doses.
Option C: Option C incorrectly states that fluvastatin is the only CYP2C9-metabolized statin and that its levels rise 4 to 5 fold with amiodarone causing rhabdomyolysis in all patients: while fluvastatin is metabolized substantially by CYP2C9, this claim is overstated; however, fluvastatin with amiodarone does warrant caution, and this option contains material inaccuracies.
Option D: Option D incorrectly states that no statin can be used with amiodarone: pravastatin and rosuvastatin are both appropriate options with established clinical use alongside amiodarone.
20. [CASE 5 — QUESTION 4]
Continuing the case: Pravastatin is substituted for simvastatin and INR is now stable at 2.6 on reduced warfarin. The patient asks about long-term monitoring requirements for amiodarone. Which of the following correctly describes the complete surveillance protocol?
A) Annual INR measurement only, all other amiodarone toxicities manifest with obvious symptoms before laboratory or imaging changes appear, making scheduled monitoring of other organ systems unjustifiable in asymptomatic patients
B) Annual thyroid function tests only, thyroid dysfunction is the most common amiodarone toxicity and is the only organ-system complication that requires scheduled surveillance in patients on maintenance doses below 300 mg daily
C) Thyroid function tests and liver function tests every 6 months, annual chest X-ray and pulmonary function tests, and annual ophthalmology review, plus continuation of close INR monitoring given the ongoing amiodarone-warfarin interaction; monitoring must continue for at least 12 months after amiodarone is eventually discontinued
D) Annual complete blood count and metabolic panel, amiodarone's primary toxicity in long-term use is bone marrow suppression and electrolyte imbalance from renal tubular effects, and these are the organ systems requiring the most systematic surveillance
E) No scheduled laboratory or imaging monitoring is required for patients who tolerate amiodarone for more than 2 years without developing symptoms, after a 2-year symptom-free period, the risk of new-onset organ toxicity is negligible and monitoring can be stopped
ANSWER: C
Rationale:
Amiodarone requires systematic multi-organ surveillance throughout the duration of therapy. The standard schedule is: thyroid function tests (TSH, free T4, free T3) every 6 months; liver function tests every 6 months; annual chest X-ray and pulmonary function tests; annual ophthalmology review. In this patient, close INR monitoring is additionally required given the ongoing amiodarone-warfarin interaction, frequency determined by INR stability. This monitoring schedule must continue for at least 12 months after amiodarone is discontinued because tissue drug levels persist for months given the 40 to 55 day half-life. Organ toxicity from amiodarone is cumulative and duration-dependent; risk does not plateau or diminish after 2 years.
Option A: Option A is incorrect: many amiodarone toxicities, including pulmonary toxicity, can develop insidiously without prominent early symptoms, and the annual CXR and PFT schedule exists specifically to detect pre-symptomatic changes.
Option B: Option B is incorrect: thyroid function tests alone are insufficient; pulmonary, hepatic, and ophthalmologic surveillance are all required components of the standard monitoring protocol.
Option D: Option D is incorrect: amiodarone does not cause bone marrow suppression or renal tubular electrolyte disorders as primary toxicities; these are not among the monitored organ systems in standard amiodarone surveillance protocols.
Option E: Option E is incorrect: organ toxicity risk from amiodarone accumulates with cumulative dose and duration and does not diminish or plateau after 2 years of symptom-free therapy; monitoring must continue throughout the period of drug use and for 12 months after stopping.
21. [CASE 6 — QUESTION 1]
A 66-year-old man with coronary artery disease, prior MI 4 years ago, EF 46%, paroxysmal atrial fibrillation, CrCl 36 mL/min, and baseline QTc 438 ms presents for rhythm control. The resident considers several antiarrhythmic options. Which of the following agents is contraindicated by the patient's renal function alone, independent of any cardiac diagnosis?
A) Amiodarone, requires CrCl above 50 mL/min for safe use due to accumulation of its active metabolite desethylamiodarone in renal impairment
B) Sotalol, eliminated entirely unchanged by the kidneys; CrCl of 36 mL/min falls below the 40 mL/min absolute contraindication threshold regardless of cardiac diagnosis
C) Dronedarone, requires CrCl above 60 mL/min due to its primary renal elimination pathway; CrCl of 36 mL/min places this patient in the contraindicated range per labeling
D) Amiodarone and dronedarone, both agents are renally eliminated and require CrCl above 45 mL/min; the patient's CrCl of 36 mL/min contraindicated both simultaneously
E) Dofetilide, a CrCl of 36 mL/min falls below the minimum threshold for dofetilide initiation, which requires CrCl of at least 40 mL/min; patients in the 20 to 40 mL/min range are not candidates for dofetilide regardless of cardiac substrate
ANSWER: B
Rationale:
Sotalol is contraindicated by renal function alone in this patient. It is eliminated entirely unchanged by the kidneys, and a CrCl below 40 mL/min represents an absolute contraindication because drug accumulation raises plasma levels, extends the half-life, amplifies QTc prolongation, and creates an unacceptable TdP risk. This patient's CrCl of 36 mL/min is below the threshold.
Option A: Option A is incorrect: amiodarone is hepatically metabolized with no clinically significant renal dose adjustment required; desethylamiodarone accumulation in renal impairment does not reach levels requiring dose modification or contraindication at CrCl 36 mL/min.
Option C: Option C is incorrect: dronedarone is primarily hepatically metabolized by CYP3A4 and does not require renal dose adjustment; it is not renally eliminated in a manner that mandates a CrCl threshold.
Option D: Option D is incorrect: amiodarone does not require CrCl above 45 mL/min and is not renally eliminated significantly; the claim that both amiodarone and dronedarone are contraindicated renally is factually incorrect.
Option E: Option E is incorrect: the dofetilide contraindication threshold based on renal function is CrCl below 20 mL/min, not below 40 mL/min; a CrCl of 36 mL/min falls in the 20 to 40 mL/min range, which requires dose reduction to 125 mcg twice daily but does not contraindicate dofetilide.
22. [CASE 6 — QUESTION 2]
Continuing the case: Sotalol has been excluded. The resident now asks whether dronedarone is appropriate. Which of the following correctly evaluates dronedarone's eligibility for this patient?
A) Dronedarone is contraindicated because the patient has prior MI, which constitutes structural heart disease meeting the ANDROMEDA exclusion criterion: ANDROMEDA contraindicated dronedarone in all patients with any history of coronary artery disease
B) Dronedarone is contraindicated because the CrCl of 36 mL/min falls below the renal threshold for dronedarone use; severe hepatic or renal impairment is listed in dronedarone labeling as a contraindication
C) Dronedarone is not contraindicated in this patient, his EF of 46% is above the HFrEF concern threshold, his AF is paroxysmal (not permanent), and he has no history of hospitalization for heart failure decompensation; the ATHENA trial supports its use in patients with preserved or mildly reduced EF and non-permanent AF
D) Dronedarone is acceptable but requires dose reduction to 200 mg twice daily in patients with prior MI and CrCl below 50 mL/min, at the reduced dose, both the cardiac and renal safety concerns are adequately addressed
E) Dronedarone is contraindicated because the patient has coronary artery disease and Class Ic agents are contraindicated in CAD; dronedarone shares the Class Ic sodium channel blocking mechanism at clinical doses and therefore carries the same CAST-derived contraindication
ANSWER: C
Rationale:
Dronedarone is not contraindicated by this patient's profile. The ANDROMEDA contraindication applies to HFrEF with NYHA Class III-IV symptoms or recently decompensated HF, not to all patients with prior MI or preserved EF. His EF of 46% is above the concern threshold, he has no history of HF hospitalization, and his AF is paroxysmal rather than permanent (which would trigger the PALLAS contraindication). Dronedarone does not require renal dose adjustment, it is primarily hepatically metabolized by CYP3A4, and severe renal impairment in isolation is not a listed contraindication at CrCl 36 mL/min. The ATHENA trial demonstrated cardiovascular benefit with dronedarone in patients with non-permanent AF and preserved or mildly reduced EF.
Option A: Option A incorrectly states that ANDROMEDA contraindicated dronedarone in all patients with any CAD history: ANDROMEDA specifically enrolled patients with severe HFrEF or recently decompensated HF; prior MI with preserved EF and no HF decompensation is not the ANDROMEDA contraindicated population.
Option B: Option B incorrectly states that CrCl 36 mL/min contraindicated dronedarone: severe renal impairment is listed as a precaution in some labeling, but dronedarone does not require renal dose adjustment and CrCl 36 mL/min does not represent a categorical contraindication.
Option D: Option D is incorrect: dronedarone is not dose-reduced based on renal function or prior MI; 400 mg twice daily is the only approved dose.
Option E: Option E is incorrect: dronedarone is a Class I through IV multi-channel agent, not a Class Ic drug; while it has some sodium channel blocking activity at pharmacological concentrations, it is not classified as a Class Ic agent and does not share the CAST-derived contraindication of flecainide and propafenone.
23. [CASE 6 — QUESTION 3]
Continuing the case: Dronedarone has been identified as acceptable. The resident now considers dofetilide. What is the correct dofetilide dose for this patient, and what additional requirement applies before it can be used?
A) Dofetilide is contraindicated in this patient because prior MI constitutes structural heart disease that excludes dofetilide use, dofetilide is approved only for patients with no structural heart disease, based on the DIAMOND-CHF design that excluded post-MI patients
B) Dofetilide 500 mcg twice daily (standard dose), his CrCl of 36 mL/min is above the contraindication threshold and the standard dose applies; the mandatory in-hospital initiation requirement does not apply in patients with prior MI because the cardiac substrate reduces the TdP risk
C) Dofetilide 125 mcg twice daily, with mandatory in-hospital initiation and QTc monitoring after each dose, his CrCl of 36 mL/min falls in the 20 to 40 mL/min range requiring dose reduction to the lowest available tier; in-hospital initiation is required for all patients regardless of renal function or cardiac diagnosis
D) Dofetilide is contraindicated because CrCl of 36 mL/min falls below the minimum threshold of 40 mL/min required for dofetilide initiation, patients in the 20 to 40 mL/min range must use amiodarone or dronedarone as alternatives
E) Dofetilide 250 mcg twice daily: CrCl of 36 mL/min places him in the 20 to 60 mL/min intermediate range that requires intermediate dosing; QTc monitoring is required only on day 1 of initiation as the primary risk window for TdP is the first 24 hours
ANSWER: A
Rationale:
Dofetilide's four-tier renal dose adjustment: CrCl greater than 60 mL/min = 500 mcg twice daily; CrCl 40 to 60 mL/min = 250 mcg twice daily; CrCl 20 to 40 mL/min = 125 mcg twice daily; CrCl below 20 mL/min = contraindicated. This patient's CrCl of 36 mL/min falls in the 20 to 40 mL/min range, requiring the lowest available dose of 125 mcg twice daily. Mandatory in-hospital initiation with continuous telemetry for at least 3 days and QTc monitoring 2 to 3 hours after each dose applies to all patients regardless of renal function or cardiac diagnosis.
Option A: Option A is incorrect: dofetilide is not limited to patients without structural heart disease; DIAMOND-CHF specifically enrolled patients with HFrEF and demonstrated safety in that structural heart disease population; prior MI with preserved EF does not contraindicate dofetilide.
Option B: Option B is incorrect: the standard 500 mcg dose applies only to CrCl above 60 mL/min; at CrCl 36 mL/min, the standard dose would cause drug accumulation and amplified QTc prolongation; the in-hospital initiation requirement is universal.
Option D: Option D is incorrect: the dofetilide renal contraindication threshold is CrCl below 20 mL/min, not below 40 mL/min; CrCl 36 mL/min is within the adjustable range requiring 125 mcg twice daily.
Option E: Option E is incorrect: CrCl 36 mL/min does not fall in a single intermediate range; it specifically falls in the 20 to 40 mL/min tier requiring 125 mcg twice daily, and QTc monitoring is required after each dose for at least 3 days, not only on day 1.
24. [CASE 6 — QUESTION 4]
Continuing the case: The team has established that both dronedarone and dofetilide (at 125 mcg twice daily) are feasible options, as is amiodarone. Which of the following best justifies selecting amiodarone as the first-line choice in this specific patient?
A) Amiodarone is preferred because it is the only Class III agent that does not require in-hospital initiation, making it the most practical option for outpatient rhythm control in a patient with CAD and reduced CrCl
B) Amiodarone is preferred because the CAST trial specifically established amiodarone as the safe alternative to Class Ic agents in post-MI patients with structural heart disease, this trial evidence makes amiodarone the guideline-mandated first-line agent in post-MI AF
C) Amiodarone is preferred in this patient because it requires no renal dose adjustment despite CrCl of 36 mL/min, has the broadest antiarrhythmic efficacy across structural substrates including CAD and mildly reduced EF, and avoids the mandatory in-hospital initiation burden of dofetilide at the lowest dose tier, though its cumulative toxicity profile requires structured long-term monitoring
D) Amiodarone is preferred because its half-life of 40 to 55 days ensures stable plasma levels that are unaffected by the patient's reduced renal function, plasma level stability is the primary advantage over dofetilide in patients with CrCl below 40 mL/min
E) Amiodarone is preferred because dronedarone and dofetilide both require concurrent anticoagulation with a specific DOAC formulation, whereas amiodarone can be used with warfarin; since this patient is on warfarin, amiodarone is the only compatible option
ANSWER: C
Rationale:
Amiodarone is a reasonable first-line choice in this patient for several practical reasons. It requires no renal dose adjustment, its hepatic CYP3A4 metabolism and large-volume tissue distribution mean that CrCl of 36 mL/min does not affect dosing or safety. It has the broadest antiarrhythmic efficacy across virtually all cardiac substrates including post-MI and mildly reduced EF. While dofetilide at 125 mcg twice daily is pharmacologically appropriate, it requires mandatory in-hospital initiation with 3 days of telemetry at the lowest dose tier, adding healthcare resource utilization. The decision should be accompanied by structured long-term monitoring for amiodarone's multi-organ toxicities.
Option A: Option A is incorrect: amiodarone does require in-hospital loading doses in the acute VT setting, though for elective AF rhythm control it can be initiated as an outpatient with oral loading; the claim that it is the only agent not requiring any in-hospital initiation overstates its convenience advantage.
Option B: Option B is incorrect: the CAST trial studied flecainide and encainide; it did not specifically establish amiodarone as the mandated alternative and did not include amiodarone as a study arm; amiodarone's post-MI safety is based on a separate evidence base.
Option D: Option D incorrectly frames plasma level stability as the primary advantage: while amiodarone's long half-life ensures stable levels, this is not the primary justification for its preference over dofetilide in this patient; the renal independence and broad efficacy are the more clinically relevant advantages.
Option E: Option E is incorrect: neither dronedarone nor dofetilide requires a specific DOAC formulation; both can be used with warfarin, and anticoagulant compatibility is not a basis for preferring amiodarone.
25. [CASE 7 — QUESTION 1]
A 57-year-old woman with no structural heart disease presents to the emergency department with symptomatic atrial flutter of 5 hours duration, ventricular rate 138 bpm, blood pressure 118/72 mmHg. Her QTc is 412 ms, potassium 4.4 mEq/L, magnesium 2.1 mg/dL, and creatinine clearance 85 mL/min. The team selects IV ibutilide for pharmacologic cardioversion. Which of the following correctly describes ibutilide's mechanism of action that makes it particularly effective for atrial flutter?
A) Ibutilide blocks IKr selectively in atrial tissue while sparing ventricular IKr, producing atrial-specific APD prolongation that terminates atrial flutter without prolonging the ventricular QTc interval or creating TdP risk
B) Ibutilide activates L-type calcium channels in atrial tissue, raising intracellular calcium to a level that terminates re-entrant flutter circuits by inducing calcium-mediated afterhyperpolarizations that reset atrial automaticity
C) Ibutilide blocks both IKr and IKs simultaneously, producing more complete repolarization prolongation than pure IKr blockers; the combined potassium channel blockade eliminates the excitable gap in flutter's macro-re-entrant circuit more completely than single-channel agents
D) Ibutilide blocks IKr and also activates a slow, sustained inward sodium current unique among Class III agents, this dual mechanism produces potent APD prolongation across cardiac tissues that eliminates the excitable gap in atrial flutter's organized macro-re-entrant circuit, achieving cardioversion rates of approximately 65 to 70% for flutter
E) Ibutilide inhibits the sodium-calcium exchanger in atrial tissue, reducing calcium overload in remodeled atrial myocytes and restoring normal action potential morphology, making the re-entrant substrate less susceptible to perpetuating flutter
ANSWER: D
Rationale:
Ibutilide has a unique dual mechanism among Class III agents: it blocks IKr and also activates a slow, sustained inward sodium current that further prolongs APD. This combination produces rapid and potent APD prolongation that effectively eliminates the excitable gap in atrial flutter's organized macro-re-entrant circuit, allowing the circulating wavefront to encounter refractory tissue and extinguish. Flutter's single organized re-entrant circuit responds more predictably to refractoriness-based termination than the multiple disorganized wavelets of AF, explaining the higher cardioversion success rate for flutter (65 to 70%) compared to AF (40 to 60%).
Option A: Option A is incorrect: ibutilide does not selectively block IKr in atrial tissue; it prolongs APD throughout the heart including the ventricles, which is why QTc prolongation and TdP are significant risks; atrial selectivity is not a feature of ibutilide's mechanism.
Option B: Option B is incorrect: ibutilide does not activate L-type calcium channels; its second mechanism is activation of a slow inward sodium current; calcium channel activation is not part of ibutilide's established pharmacology.
Option C: Option C is incorrect: ibutilide blocks IKr and activates slow inward sodium current; it does not block IKs; combined IKr plus IKs blockade describes amiodarone's mechanism, not ibutilide's.
Option E: Option E is incorrect: ibutilide does not inhibit the sodium-calcium exchanger; NCX inhibition is proposed as a mechanism relevant to dronedarone's hemodynamic effects in HFrEF; it is not an established mechanism for ibutilide.
26. [CASE 7 — QUESTION 2]
Continuing the case: Ibutilide 1 mg IV is administered over 10 minutes. The patient converts to sinus rhythm at 18 minutes. Twenty-eight minutes after the infusion ended, the monitor alarms: QTc is now 538 ms and a run of 8 beats of polymorphic wide-complex tachycardia with a twisting QRS axis terminates spontaneously. The patient is asymptomatic with blood pressure 122/76 mmHg. What is the correct immediate management?
A) Administer IV amiodarone 150 mg over 10 minutes, amiodarone provides Class I through IV counter-regulation of the IKr-driven QT prolongation from ibutilide and is the first-line agent for post-ibutilide TdP in the setting of preserved hemodynamics
B) Administer IV magnesium sulfate 2 g over 1 to 2 minutes as first-line pharmacologic treatment, magnesium suppresses EADs by blocking ICaL regardless of serum magnesium level, and should be given immediately with continued monitoring; if TdP recurs, isoproterenol or overdrive pacing should be considered
C) Perform immediate synchronized DC cardioversion at 100 J, a QTc of 538 ms with documented polymorphic VT requires immediate electrical termination regardless of hemodynamic stability
D) Discharge the patient, the TdP episode was self-terminating and the patient is asymptomatic; self-terminating TdP after ibutilide does not require treatment beyond continued monitoring until the QTc normalizes to within 10% of baseline
E) Administer IV lidocaine 1.5 mg/kg, lidocaine shortens ventricular APD by blocking late inward sodium current, directly opposing ibutilide's slow inward sodium current mechanism and providing targeted reversal of the QT prolongation responsible for TdP
ANSWER: B
Rationale:
This is ibutilide-induced TdP in a hemodynamically stable patient. The correct first-line pharmacologic treatment is IV magnesium sulfate 2 g over 1 to 2 minutes, regardless of serum magnesium level. Magnesium suppresses EAD formation by blocking ICaL, reducing the inward trigger current that drives TdP. The patient should be closely monitored for recurrence. If TdP recurs and is pause-dependent, increasing heart rate with IV isoproterenol or overdrive pacing at 90 to 110 bpm eliminates the pauses triggering EAD formation. Because the patient has already been in the post-infusion monitoring period, the team should also ensure resuscitation equipment remains immediately available.
Option A: Option A is incorrect: amiodarone is a QT-prolonging agent and would worsen the proarrhythmic substrate; IV amiodarone is contraindicated in the setting of active QT-prolongation-driven TdP.
Option C: Option C is incorrect: DC cardioversion is appropriate for hemodynamically unstable TdP; this patient has a blood pressure of 122/76 mmHg and is asymptomatic; immediate cardioversion of a self-terminating episode in a stable patient is not indicated when pharmacologic management is available.
Option D: Option D is incorrect: self-terminating TdP after ibutilide is a serious adverse event requiring immediate treatment and extended monitoring; discharge would be inappropriate and potentially dangerous as further episodes may occur and could be hemodynamically unstable.
Option E: Option E is incorrect: while lidocaine may theoretically shorten APD, it is not the established first-line treatment for post-ibutilide TdP; its ability to antagonize ibutilide's slow inward sodium current at standard clinical doses is limited and unpredictable, and magnesium is the established first-line agent.
27. [CASE 7 — QUESTION 3]
Continuing the case: IV magnesium 2 g is administered. Over the next 30 minutes the patient has three more TdP episodes, each 6 to 12 seconds, each preceded by a pause following a PVC. The QTc remains at 526 ms. Blood pressure is 116/70 mmHg and the patient remains conscious though anxious. Which of the following correctly identifies the mechanism of recurrence and the definitive next management step?
A) The recurrent TdP reflects catecholamine-sensitive triggered activity from sympathetic surges, the correct next step is IV metoprolol 5 mg to suppress adrenergic triggering and reduce heart rate, thereby eliminating the DAD-driven mechanism responsible for each episode
B) The recurrent TdP reflects fixed anatomical re-entry in an area of atrial fibrosis unmasked by ibutilide, the correct next step is synchronized DC cardioversion at 200 J to interrupt the re-entrant circuit and restore organized ventricular activation
C) The recurrent TdP reflects myocardial ischemia precipitated by the tachycardia, the correct next step is urgent coronary angiography and IV heparin, as the QTc prolongation is a manifestation of ischemia-related heterogeneity of repolarization
D) The recurrent TdP is pause-dependent, triggered by EAD formation during the post-extrasystolic pause, the correct next step is IV isoproterenol infusion or temporary transvenous overdrive pacing at 90 to 110 bpm to eliminate the pauses and suppress EAD formation
E) The recurrent TdP reflects direct magnesium deficiency despite normal serum levels, a second bolus of magnesium 4 g over 5 minutes followed by a continuous infusion of 2 g per hour is the definitive treatment to achieve the tissue magnesium levels required to suppress EAD formation
ANSWER: D
Rationale:
The pattern, each TdP episode preceded by a PVC followed by a pause, with the episode triggering from the long RR interval after the PVC, is the hallmark of pause-dependent TdP. Ibutilide's prolonged APD effect persists well after plasma clearance due to pharmacodynamic persistence in myocardial tissue. During the post-extrasystolic pause, APD is maximally prolonged at the slow effective rate due to reverse use-dependence, generating EADs that trigger the next episode. Having already administered magnesium without suppressing recurrence, the definitive next step is to eliminate the pauses by increasing the heart rate. IV isoproterenol infusion at low doses to increase sinus rate to 90 to 110 bpm, or temporary transvenous overdrive pacing at the same rate, prevents the post-extrasystolic pauses, shortens APD, and suppresses EAD formation.
Option A: Option A incorrectly identifies catecholamine-sensitive DAD-driven triggered activity as the mechanism: the pause-dependent pattern with short-long-short RR sequences identifies EAD-driven TdP, not DAD-driven arrhythmia; beta-blockade would slow the heart rate and worsen pause-dependent TdP.
Option B: Option B incorrectly identifies fixed anatomical re-entry in atrial fibrosis: TdP is a ventricular arrhythmia from EAD-mediated triggered activity in ventricular myocardium, not a fixed re-entrant atrial circuit; the polymorphic twisting QRS of TdP is characteristic of a functional, not anatomical, re-entrant mechanism.
Option C: Option C incorrectly identifies myocardial ischemia as the cause: the patient has no structural heart disease and the QTc prolongation with pause-dependent pattern is fully explained by ibutilide's pharmacodynamic effect; acute coronary angiography is not indicated.
Option E: Option E incorrectly proposes higher-dose magnesium as the definitive treatment: while a second magnesium bolus may be given, elevated doses of magnesium do not resolve pause-dependent TdP in the same way that heart rate elevation does; the definitive approach for pause-dependent TdP after magnesium is heart rate acceleration.
28. [CASE 7 — QUESTION 4]
Continuing the case: Isoproterenol is started and the TdP episodes cease. The patient stabilizes and the QTc normalizes to 428 ms over the next 2 hours. The attending asks what pre-treatment steps should have been performed before administering ibutilide that might have reduced the TdP risk in this patient. Which of the following correctly identifies the mandatory pre-treatment requirements for ibutilide?
A) Pre-treatment with oral flecainide 200 mg taken 1 hour before ibutilide infusion: Class Ic sodium channel blockade reduces the excitable gap in atrial flutter and increases the likelihood of cardioversion, lowering the total ibutilide dose needed and thereby reducing TdP risk
B) Measurement and correction of serum electrolytes before ibutilide administration, potassium should be at least 4.0 mEq/L and magnesium at least 2.0 mg/dL before infusion; hypokalemia and hypomagnesemia amplify IKr blockade-driven APD prolongation and substantially increase TdP risk
C) In-hospital initiation over 3 days with continuous telemetry, ibutilide shares the same mandatory 3-day in-hospital initiation requirement as sotalol and dofetilide, given their shared IKr-blocking mechanism and class-wide TdP risk
D) Pre-treatment with IV calcium gluconate 1 g to stabilize the myocardial membrane and reduce the sensitivity of ventricular myocytes to IKr blockade-driven EAD formation before ibutilide infusion
E) Pre-treatment with IV amiodarone 150 mg over 10 minutes to extend the effective refractory period uniformly across cardiac tissues before ibutilide infusion, reducing heterogeneity of repolarization and lowering the TdP risk during the flutter cardioversion attempt
ANSWER: A
Rationale:
Before administering ibutilide, serum potassium and magnesium must be measured and corrected to adequate levels: potassium at or above 4.0 mEq/L and magnesium at or above 2.0 mg/dL. This is a mandatory pre-treatment requirement specified in ibutilide prescribing guidelines. Hypokalemia reduces the driving force for outward repolarizing currents and amplifies IKr blockade-driven APD prolongation; hypomagnesemia lowers the threshold for EAD formation by reducing ICaL-suppressing effects of adequate magnesium. In this patient, electrolytes were within the acceptable range (K 4.4, Mg 2.1) and this requirement was met, but the question correctly identifies it as the key mandatory pre-treatment step.
Option A: Option A is incorrect: pre-treatment with oral flecainide is not a requirement or recommendation before ibutilide; Class Ic agents carry significant proarrhythmic risk in combination with Class III agents and would not be used as pre-treatment; this option describes a clinically dangerous and evidence-free practice.
Option C: Option C is incorrect: ibutilide does not require a 3-day in-hospital initiation period; it is an acute IV agent administered in a monitored setting with post-infusion monitoring for 4 hours, not a chronic oral agent requiring multi-day initiation monitoring.
Option D: Option D is incorrect: pre-treatment with IV calcium gluconate is not a requirement or standard practice before ibutilide; calcium gluconate is used to reverse magnesium toxicity or hyperkalemia, not to pre-condition the myocardium against IKr blockade.
Option E: Option E is incorrect: pre-treatment with IV amiodarone before ibutilide is not standard practice; amiodarone is itself a QT-prolonging agent, and combining it with ibutilide would amplify QT prolongation and TdP risk rather than reducing it.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.